MET and lung cancer: Upon activation, MET dimerisation and tyrosine phosphorylation occur, which activates downstream signalling pathways such as PI3K/AKT, RAS/MAPK, STAT and Wnt/β-catenin, etc., which promote the survival, proliferation, invasion and drug resistance in lung cancer [52].